Neck News and Research

RSS

NCI awards Altor Bioscience a $3 MM grant to develop its targeted cancer therapeutic ALT-801

Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development of ALT-801, a novel tumor-targeted immunotherapeutic designed to improve the efficacy and safety of the FDA-approved anticancer cytokine, interleukin-2 (IL-2).

25 Sep 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

Scientist reveals that selecting optimal radiation dosage for a patient is possible

An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.

24 Sep 2009

New palate reconstruction technique for post tonsil cancer surgery

A new technique for reconstructing the palate after surgery for tonsil cancer maintained patients' ability to speak clearly and eat most foods, a new study shows.

23 Sep 2009

FDA warns: Personal emergency response buttons are a potential choking hazard

The U.S. Food and Drug Administration today cautioned users of personal emergency response buttons worn around the neck of a potential choking hazard associated with this product.

23 Sep 2009

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009

Moses Cone Health System installs TomoTherapy cancer treatment system

TomoTherapy Incorporated announced today that Moses Cone Health System has installed North Carolina's first TomoTherapy® cancer treatment system at the Moses Cone Regional Cancer Center in Greensboro, N.C.

22 Sep 2009

Phase 1 clinical trial results evaluating ARIAD's investigational mTOR inhibitor ridaforolimus

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.

21 Sep 2009

New interferon/lovastatin treatment to battle cancer

For selected patients, he decided he might have something better. He now has opened NeoPlas Innovation in Nashville to offer the combination "off-label" treatment on an outpatient basis.

21 Sep 2009

Research reveals that reactive oxygen inhibition can limit cancer cell invasion

Researchers at the Burnham Institute for Medical Research (Burnham) have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis.

17 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

New intraoperative nerve integrity monitors from Medtronic

Medtronic (NYSE: MDT) recently announced the launch of the NIM-Response® 3.0 and NIM-Neuro® 3.0 intraoperative nerve integrity monitors designed for a variety of surgeons, including ear, nose, and throat (ENT); endocrine; general; and peripheral surgeons.

17 Sep 2009

Premion commences cancer treatment with Varian's RapidArc radiotherapy technology

Cancer patients in Australia have gained access to advanced RapidArc(R) radiotherapy treatments from Varian Medical Systems (NYSE: VAR) with its introduction by the leading radiation oncology provider in Queensland. Premion, which operates five cancer centers in Queensland, has treated more than a dozen prostate cancer patients to date with this fast, precise and efficient technique at its Chermside treatment center in Brisbane.

16 Sep 2009

FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX

BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck.

15 Sep 2009

Clinical Professor of Surgery featured in The Doctors medical show

Dr. Dennis Hurwitz F.A.C.S., founder of the Hurwitz Center for Plastic Surgery, and Clinical Professor of Surgery (Plastic) at the University of Pittsburgh Medical School was featured today on the hit medical show "The Doctors". Dr. Hurwitz discussed the first few stages of an extreme patient makeover he performed on a local Pittsburgh resident.

15 Sep 2009

Anti-fungal pill found to be effective for treating oral candidiasis

A once-daily medication option for treating the most common mouth infection in HIV/AIDS patients has shown to be just as effective and safe as taking an anti-fungal pill five times a day, according to a Henry Ford Hospital study.

15 Sep 2009

Particle beam radiation therapy for cancer cure is better than traditional radiation method

Particle beam radiation therapy, a technology used to treat several types of cancer, is considered by some clinicians to be better than traditional radiation, but there is limited evidence about its safety compared with other types of radiation therapy, according to a new comparative effectiveness report funded by HHS' Agency for Healthcare Research and Quality.

15 Sep 2009

Phase III results of Lauriad presented at the 49th Annual ICAAC

BioAlliance Pharma has attended the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco to present results on miconazole Lauriad and anti-integrase inhibitor.

15 Sep 2009

miR-200 supression shifts primary lung cancer to metastatic disease

Primary lung cancer shifts to metastatic disease by suppressing a family of small molecules that normally locks the tumor in a noninvasive state, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 15 edition of Genes and Development.

15 Sep 2009

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.

15 Sep 2009